Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia by Lehtinen, Matti et al.
Chlamydia trachomatis infection and risk of cervical
intraepithelial neoplasia
Matti Lehtinen,
1 Kevin A Ault,
2 Erika Lyytikainen,
3 Joakim Dillner,
4,5,6
Suzanne M Garland,
7,8 Daron G Ferris,
9,10 Laura A Koutsky,
11 Heather L Sings,
12
Shuang Lu,
12 Richard M Haupt,
12 Jorma Paavonen,
13 for the FUTURE I and II Study
Group
ABSTRACT
Objectives High-risk human papillomavirus (hrHPV) is the
primary cause of cervical cancer. As Chlamydia
trachomatis is also linked to cervical cancer, its role as
a potential co-factor in the development of cervical
intraepithelial neoplasia (CIN) grade 2 or higher was
examined.
Methods The placebo arms of two large, multinational,
clinical trials of an HPV6/11/16/18 vaccine were
combined. A total of 8441 healthy women aged
15e26 years underwent cervicovaginal cytology
(Papanicolaou (Pap) testing) sampling and C trachomatis
testing at day 1 and every 12 months thereafter for up to
4 years. Protocol-speciﬁed guidelines were used to triage
participants with Pap abnormalities to colposcopy and
deﬁnitive therapy. The main outcome measured was
CIN.
Results At baseline, 2629 (31.1%) tested positive for
hrHPV DNA and 354 (4.2%) tested positive for C
trachomatis. Among those with HPV16/18 infection
(n¼965; 11.4%) or without HPV16/18 infection
(n¼7382, 87.5%), the hazard ratios (HRs) associated
with development of any CIN grade 2 according to
baseline C trachomatis status were 1.82 (95% CI: 1.06 to
3.14) and 1.74 (95% CI 1.05 to 2.90), respectively. The
results were comparable when only the 12 most
common hrHPV infections were considered, but the
excess risk disappeared when the outcome was
expanded to include CIN grade 3 or worse.
Conclusion Further studies based on larger cohorts with
longitudinal follow-up in relation to the C trachomatis
acquisition and a thorough evaluation of temporal
relationships of infections with hrHPV types, C
trachomatis and cervical neoplasia are needed to
demonstrate whether and how in some situations C
trachomatis sets the stage for cervical carcinogenesis.
Trial registration NCT00092521 and NCT00092534.
INTRODUCTION
Infection with the highly prevalent oncogenic
human papillomaviruses (HPVs) (lifetime risk
70e80%), most notably with HPV types 16 and 18,
is the primary cause of cervical cancer.
1 Past infec-
tion with Chlamydia trachomatis has also been
linked to the development of cervical cancer, as
demonstrated both in prospective seroepidemio-
logical studies and PCR-based studies using archival
cytological materials.
2e5
The pathogenesis of C trachomatis in cervical
intraepithelial neoplasia (CIN) remains unknown,
but original observations
6 and independent, large-
scale, longitudinal epidemiological studies
578
suggest that C trachomatis may be involved in
cervical carcinogenesis. By inducing cervical meta-
plasia C trachomatis infection can provide target
cells for acquisition of HPV (especially HPV
type 18).
46On the other hand, by causing local
immunoperturbation it may interfere with
immune surveillance of persistent infection with
hrHPV types.
9 These two alternatives are
supported by cohort studies that show that C
trachomatis infection is a risk factor for both inci-
dent hrHPV infection and persistence of hrHPV
DNA.
10e13 However, evidence of C trachomatis
infection increasing the risk of the development of
CIN, among those with or without hrHPV infec-
tion at the baseline, is still missing. We used a joint
cohort from two placebo-controlled trials of
a quadrivalent HPV6/11/16/18 vaccine to examine
the role of C trachomatis infection as an independent
co-factor (possibly related to HPV acquisition)
or HPV-dependent co-factor (related to HPV
persistence) in the development of CIN.
METHODS
A cohort of 17622 women aged 15e26 years was
enrolled in two multinational trials which evalu-
ated the efﬁcacy and safety of a quadrivalent
HPV6/11/16/18 virus-like particle vaccine
(GARDASIL/SILGARD, Merck Sharp & Dohme,
Whitehouse Station, New Jersey, USA).
14 15 Both
studies were approved by the institutional review
boards (ethical review committees) at participating
centres and informed consent was received from all
the participants enrolled. The study designs and
results of the primary hypotheses have been
described, following the consort guidelines.
14 15 The
trials recruited healthy women who, at enrolment
(day 1), reported having had 0e4 sex partners
during their lifetime, except in Finland, where age
over 17 years was used as an exclusion criterion.
As the study had no screening phase, the trials
allowed the enrolment of women who had previ-
ously been or were currently infected with any of
the HPV types known to infect the anogenital
tract. All participants were tested for cervical
cytological abnormalities, and C trachomatis at
baseline and 12-monthly intervals in the FUTURE I
and FUTURE II trials, respectively, for immediate
treatment after which they were again eligible for
the follow-up.
14 15 In this study, the ﬁnal cohort
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Epidemiologyconsisted of 8441 women who were randomised to the placebo
arms of the two trials only, and followed approximately
3.7 years on average, with 25th and 75th percentiles of 3.5 and
3.9 years, respectively (maximum follow-up 4.9 years).
C trachomatis serology was not performed.
Anogenital swabs collected at baseline, and all tissues
collected from deﬁnitive therapy and excisions (including biopsy
specimens) were tested with a PCR-based assay
16e18 for 14
HPV types, including the four vaccine types (ie, HPV6, 11, 16
and 18) and 10 other hrHPV types (HPV31, 33, 35, 39, 45, 51, 52,
56, 58 and 59) which are the most common hrHPV types in
cervical cancer worldwide.
19 All tissue specimens, including
those from deﬁnitive therapy and excision (including all biopsy
specimens), were subjected to histopathological review by
a blinded pathology panel.
This post hoc analysis was performed to assess the indepen-
dent role of baseline C trachomatis in the development of CIN by
comparing results from the HPV-stratiﬁed and HPV-adjusted
analyses. The following CIN endpoints were evaluated: 1) CIN
grade 2 (CIN2) due to any HPV type; 2) CIN2 related to
a hrHPV type; 3) CIN grade 3 (CIN3) or adenocarcinoma in situ
(AIS) due to any HPV type and 4) CIN3 or AIS related to
a hrHPV type. High-risk types included the following 12 HPV
types: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59. In our
longitudinal follow-up study, risks of developing CIN2 and
CIN3 or AIS were evaluated separately to distinguish early and
later associations of C trachomatis with cervical intraepithelial
neoplasia. Rates of these endpoints were summarised based on
the number of women with a lesion per 100 person-years at risk.
Univariate and multivariate Cox models
20 were used to
analyse the impact of baseline C trachomatis status on the end
points. The univariate analysis stratiﬁed by HPV baseline status
was ﬁrst used for the evaluation of the impact of baseline C
trachomatis status (positive vs negative) on the RR of developing
CIN2 and CIN3 or AIS separately in baseline HPV-positive or
HPV-negative individuals. Thereafter, the multivariate models
adjusting for covariates such as baseline status (HPV positive or
negative), age at study entry, number of lifetime sexual partners
and smoking status (current smoker, former smoker, never
smoked) were used to conﬁrm the nature (HPV dependent or
independent) of the C trachomatis associated risk. In the models
pertaining to CIN endpoints due to any HPV type, HPV baseline
status was deﬁned based on positivity to HPV 16 or HPV 18. In
the models of CIN endpoints, due to hrHPV types, HPV baseline
status was based on positivity for any of the 12 tested types.
HRs and 95% CIs were calculated from both the univariate
and multivariate models. In the latter the interaction between C
trachomatis and baseline HPV status was assessed by including an
interaction term in the Cox multivariate model. From this
model, the impact of C trachomatis was estimated within each
baseline HPV status (HPV negative and HPV positive) group
to compare, at the baseline, the HPV-independent and
HPV-dependent risk estimates.
RESULTS
Of the 8812 women randomised to the placebo arms, 8441 had
non-missing data for C trachomatis infection at enrolment, with
354 of 8441 (4.2%) positive for C trachomatis, and 2629 (31.1%)
positive for hrHPV DNA at baseline. The age distribution, age at
sexual debut and lifetime number of sex partners were similar
between the C trachomatis-positive and C trachomatis-negative
women (table 1). Smoking was more common among the
former (32.8% vs 26.8%). The frequency of any squamous
intraepithelial lesions, HPV16/18 infection and infections with
$1 of 14 tested HPV types was twofold higher among baseline
C trachomatis-positive women compared with C trachomatis
negative women (table 1).
Crude (univariate analysis) HRs suggested that women with
C trachomatis at baseline were about two times more likely to
develop CIN2 than those without (table 2). After adjusting
(multivariate analysis) for HPV16/18 status, age at study entry,
number of lifetime sexual partners and smoking status, women
with C trachomatis at baseline were 1.78 times more likely to
develop CIN2 due to any HPV type (p¼0.002, table 2) than
those without C trachomatis. Finally, in the multivariate analysis
among women with HPV16/18 infection at baseline, those with
C trachomatis at baseline were 1.82 times more likely to develop
CIN2 due to any HPV type compared with those without
(p¼0.030, table 2). A similar point estimate (HR 1.74, p¼0.033,
table 2) was observed among those without HPV16/18 infec-
tion. In corresponding, multivariate analyses among women
with at least one of the 12 tested hrHPV types at baseline, those
with C trachomatis were 1.59 times more likely to develop CIN2
related to one of the 12 tested hrHPVs compared with those
without (p¼0.033, table 2), among baseline hrHPV negative
women, the point estimate even if not statistically signiﬁcant
was not materially different (HR 1.35).
When the end points were any HPV- or hrHPV-positive CIN3
or AIS, the point estimates in the total univariate analysis were
statistically signiﬁcant (HR for those with vs those without
C trachomatis¼1.74, 95% CI: 1.10 to 2.74, p¼0.017, 1.82, 95% CI:
1.15 to 2.87, p¼0.010, respectively, table 3). However, in the
multivariate analysis among HPV16/18, the positives also
approached unity (HR for those with vs those without
C trachomatis¼1.19, 95% CI: 0.62 to 2.28, p¼0.601, table 3). This
was true also for the 12 hrHPV associated point estimates (HR
for those with vs those without C trachomatis¼1.05, 95%
CI: 0.63 to 1.75, p¼0.851, table 3).
DISCUSSION
Our results suggest that if infection with C trachomatis plays an
independent co-factor role in the development of cervical
neoplasia,
21 22 the effect is likely to take place at an early stage of
cervical carcinogenesis and/or restricted to some cases only. Our
data are well in line with previous reports. Studies showing an
effect of C trachomatis on late outcomes, such as cervical cancer,
have either used long follow-up times or the highest point
Table 1 Baseline characteristics of the study population
Chlamydia
trachomatis positive
at day 1 (N[354)
C trachomatis
negative at day
1( N [8087)
Mean age (years) 6SD 20.262.0 20.062.1
Age at ﬁrst sexual intercourse
6SD (among non-virgins)
16.561.8 16.761.9
Median lifetime number of sexual
partners (IQR)
2( 2 e3) 2 (1e3)
Current smoker 116/354 (32.8%) 2166/8087 (26.8%)
Any squamous intraepithelial
neoplasia present*
69/337 (20.5%) 860/7854 (10.9%)
Positive (by PCR) to $1o f1 4 y
tested HPV types
208/354 (58.8%) 2540/8087 (31.4%)
Positive (by PCR) to $1o f1 2 z
tested hrHPV types
204/354 (57.6%) 2425/8087 (30.0%)
Positive (by PCR) to HPV16
and/or 18
81/354 (22.9%) 884/8087 (10.9%)
*Denominator includes only those women with a satisfactory day 1 Pap test result.
yIncludes HPV6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59.
zIncludes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59.
hrHPV, high-risk HPV.
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Epidemiologyestimates have been obtained for cases with longest lag time
between C trachomatis exposure and the outcome.
2e5
The study has several strengths. This large cohort study
enrolled a diverse population of young women participating in
developed and developing countries. High diagnostic accuracy for
CIN determination was provided by a panel of expert patholo-
gists. In addition, there was well controlled, sensitive testing for
HPV DNA and for baseline C trachomatis infection by PCR.
Though this was a relatively large study, the quadrivalent vaccine
clinical trials were neither designed nor powered to examine the
role ofC trachomatis infection asa co-factor in the development of
CIN. Other limitations of this post hoc analysis study include
the limited follow-up time, and the fact that residual
confounding by unknown factors could not be eliminated.
Overall, any effects of C trachomatis were expected to be seen on
the earliest CIN endpoints with the most statistical power.
The questions of which of the two infections, HPV or
Ct r a c h o m a t i s , has to occur ﬁrst, and whether the latter increases
the risk of acquiring HPV could not be fully answered with the
obtained results. The fact that the Ct r a c h o m a t i sassociated rela-
tive risk (RR) of developing CIN2 was statistically signiﬁcant
albeit comparable both before and after acquisition of HPV16/18
(independently of baseline HPV positivity) suggests that the order
of the two infections is not important in cervical carcinogenesis.
Because of this result (independent risk factor role of Ct r a c h o -
matis) and due to the study setting (screening and treatment of C
trachomatis infection during the active follow-up), it is not really
possible to make even indirect inferences on the possible increased
acquisition of HPV infection following Ct r a c h o m a t i sinfection. If
Ct r a c h o m a t i shad been proved to be a risk factor only in baseline
HPV negatives or in baseline HPV positives, the increased acqui-
sition hypothesis could have been veriﬁed or falsiﬁed.
Several cohort studies have indicated that C trachomatis
exposure increases the tendency for HPV infection to
persist.
10e13 This effect on persistence could translate to an
associated increased risk for cervical cancer. An analysis of the
HPV-stratiﬁed and HPV-adjusted risk estimates obtained both in
the univariate and multivariate analyses (with very limited
residual confounding from hrHPVs because of the highly sensi-
tive HPV PCR) suggests that the C trachomatis associated RR of
developing CIN2 is comparable both before and after acquisition
of HPV. Furthermore, no interaction between the two microor-
ganisms was observed. Thus, C trachomatis may not act in
the cervical carcinogenesis by promotion of persistent HPV
infection.
In the present study, the observation that baseline C tracho-
matis positivity was associated with CIN2 but not with CIN3
suggests that C trachomatis infection might facilitate the devel-
opment of early cervical lesions although there is a possibility
that the difference in results for CIN2 and CIN3 might be due
to chance. On the other hand, a proportion of both CIN2 and
CIN3 lesions regress. This, and the fact that C trachomatis in
other longitudinal studies has been associated with early stages
of lesions developing to cervical cancer
2e6 suggest that C
trachomatis may have an early role in cervical carcinogenesis in
a proportion of cases. The pathobiology of its possible role,
however, remains open.
We do not know for how long the C trachomatis-positive
individuals had been positive before entering the study. Testing
and treatment of C trachomatis infection during the active
follow-up, as well as the relatively small number of patients, also
reduced the power of our study in assessing C trachomatis asso-
ciated risks, especially the risk of CIN3 and AIS, longitudinally.
The observed CIN2 association could be spurious and due to
Table 2 Multivariate and univariate analysis for risk (HR) of developing cervical intraepithelial neoplasia grade 2 (CIN2) according to baseline
Chlamydia trachomatis and high-risk human papillomavirus (hrHPV) DNA status
N
C trachomatis
positive at day 1 (N[354)
C trachomatis negative
at day 1 (N[8087) Multivariate model Univariate model
n
No of women with
a CIN2 lesion due to
any HPV type Rate* n
No of women with
a CIN2 lesion due to
any HPV type Rate* HRy (95% CI) p-valuez HRy (95% CI) p-valuez
CIN2 due to any HPV type
Total 8441 354 32 2.76 8087 330 1.18 1.78
(1.23 to 2.58)
0.002 2.28
(1.58 to 3.28)
<0.0001
Negative for HPV16
and 18
7382 268 16 1.76 7114 226 0.91 1.74
(1.05 to 2.90)
0.033 1.86
(1.12 to 3.09)
0.017
Positive for HPV16
and/or 18
965 81 15 6.47 884 101 3.67 1.82
(1.06 to 3.14)
0.030 1.74
(1.01 to 3.00)
0.045
Nn
No of women with
a CIN2 lesion due to
hrHPV typex Rate* n
No of women with
a CIN2 lesion due to
hrHPV typex Rate* HRy (95% CI) p-valuez HRy (95% CI) p-valuez
CIN2 due to hrHPVx type
Total 8441 354 29 2.49 8087 296 1.06 1.55
(1.05 to 2.30)
0.028 2.28
(1.56 to 3.34)
<0.0001
Negative for all 12
testedx hrHPV types
5689 143 4 0.8 5546 114 0.58 1.35
(0.50 to 3.67)
0.554 1.33
(0.49 to 3.59)
0.579
Positive for $1o f1 2
testedx hrHPV types
2629 204 24 3.75 2425 179 2.26 1.59
(1.04 to 2.44)
0.033 1.63
(1.07 to 2.50)
0.024
N: Total number of women with non-missing Chlamydia status and respective PCR status and at least one follow-up visit.
n: Number of women with positive/negative Chlamydia status and positive/negative PCR status and at least one follow-up visit.
*Number of women with a lesion per 100 person-years at risk.
yHR associated with being positive versus negative to Chlamydia at baseline for each model. For the ‘univariatedtotal’ estimates, HR is calculated using the full data. For the
‘univariatednegative/positive’ estimates, HR is calculated using data from each stratiﬁed HPV baseline status group. For the ‘multivariatedtotal’ estimates, HR is calculated after adjusting for
HPV baseline status (positive or negative), age at study entry, number of lifetime sexual partners and smoking status (current smoker, former smoker, never smoked). Interactions between
baseline HPV status and Chlamydia status were tested and proved to be insigniﬁcant (p-values of interactions are 0.905 and 0.768 in the models of CIN2 due to any HPV type and CIN2 due to
any hrHPV type, respectively). For the ‘multivariatednegative/positive’ estimates, HR is estimated within each HPV baseline status group after including the interaction term between baseline
Chlamydia status and baseline HPV status and adjusting for age at study entry, number of lifetime sexual partners and smoking status.
zp Value shows how signiﬁcantly the estimated HRs differ from 1.
xIncludes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.
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Epidemiologyconfounding by the relationship between C trachomatis and
infection with HPV types that have not been tested for.
However, the difference in the oncogenicity between the tested
and non-tested hrHPV types, and the low prevalence of the
latter,
23 makes this unlikely.
Further studies based on larger cohorts with longitudinal
follow-up in relation to the C trachomatis acquisition and
a thorough evaluation of temporal relationships of infections
with hrHPV types, C trachomatis and cervical neoplasia are
needed to demonstrate whether in some situations C trachomatis
sets the stage for cervical carcinogenesis.
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Table 3 Multivariate and univariate analysis for risk (HR, HR) of developing cervical intraepithelial neoplasia grade 3 (CIN3) or adenocarcinoma in situ
(AIS) according to baseline Chlamydia trachomatis and high-risk human papillomavirus (hrHPV) DNA status
N
C trachomatis
positive at day 1 (N[354)
C trachomatis negative
at day 1 (N[8087) Multivariate model Univariate model
n
No of women with
a CIN3/AIS lesion due
to any HPV type Rate* n
No of women with
a CIN3/AIS lesion due
to any HPV type Rate* HRy (95% CI) p-valuez HRy (95% CI) p-valuez
CIN3/AIS due to any HPV type
Total 8441 354 20 1.71 8087 267 0.96 1.31
(0.83 to 2.06)
0.253 1.74
(1.10 to 2.74)
0.017
Negative for HPV16
and 18
7382 268 10 1.09 7114 163 0.66 1.44
(0.76 to 2.73)
0.265 1.61
(0.85 to 3.05)
0.146
Positive for HPV16
and/or 18
965 81 10 4.3 884 103 3.71 1.19
(0.62 to 2.28)
0.601 1.15
(0.60 to 2.21)
0.666
Nn
No of women with
a CIN3/AIS lesion due
to hrHPV typex Rate* n
No of women with
a CIN3/AIS lesion due
to hrHPV typex Rate* HRy (95% CI) p-valuez HRy (95% CI) p-valuez
CIN3/AIS due to hrHPVx type
Total 8441 354 20 1.71 8087 256 0.92 1.10
(0.69 to 1.76)
0.693 1.82
(1.15 to 2.87)
0.010
Negative for all 12
testedx hrHPV types
5689 143 3 0.6 5546 77 0.39 1.43
(0.45 to 4.55)
0.540 1.50
(0.47 to 4.77)
0.488
Positive for $1o f1 2
testedx hrHPV types
2629 204 16 2.48 2425 179 2.25 1.05
(0.63 to 1.75)
0.851 1.09
(0.65 to 1.81)
0.750
N: Total number of women with non-missing Chlamydia status and respective PCR status and at least one follow-up visit.
n: Number of women with positive/negative Chlamydia status and positive/negative PCR status and at least one follow-up visit.
*Number of women with a lesion per 100 person-years at risk.
yHR associated with being positive versus negative to Chlamydia at baseline for each model. For the ‘univariatedtotal’ estimates, HR is calculated using the full data. For the
‘univariatednegative/positive’ estimates, HR is calculated using data from each stratiﬁed HPV baseline status data. For the ‘multivariatedtotal’ estimates, HR is calculated after adjusting for
HPV baseline status (positive or negative), age at study entry, number of lifetime sexual partners, and smoking status (current smoker, former smoker, never smoked). Interactions between
baseline HPV status and Chlamydia status were tested and proven to be insigniﬁcant (P-values of interactions are 0.683 and 0.628 in the models of CIN3/AIS due to any HPV type and CIN3/AIS
due to any hrHPV type, respectively). For the ‘multivariatednegative/positive’ estimates, HR is estimated within each HPV baseline status group after including the interaction term between
baseline Chlamydia status and baseline HPV status and adjusting for age at study entry, number of lifetime sexual partners, and smoking status.
zp Value shows how signiﬁcantly the estimated HRs differ from 1.
xIncludes HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59.
Key Messages
< We conducted a longitudinal, 4-year follow-up study on the
role of Chlamydia trachomatis as a risk factor for cervical
intraepithelial neoplasia (CIN) in a sizeable cohort of 8441
placebo vaccinated 15e26-year-old women.
< Baseline C trachomatis PCR positivity was an independent,
albeit moderate (HR 1.8) risk factor for the development of
CIN2 with materially indistinguishable point estimates in both
baseline HPV16/18 positives and HPV16/18 negatives.
< C trachomatis may be involved only in the early stages of
cervical carcinogenesis as no increased risk associated with C
trachomatis was found for CIN3. The pathobiology of its
possible role, however, remains open.
< Further studies based on larger cohorts with longitudinal
follow-up in relation to the C trachomatis acquisition and
a thorough evaluation of temporal relationships of infections
with hrHPV types, C trachomatis and cervical neoplasia are
needed to demonstrate whether and how in some situations C
trachomatis sets the stage for cervical carcinogenesis.
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